Application to FDA for lonafarnib approval is COMPLETE!

During an otherwise difficult time for our world, I am happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval – in Europe and the US – of the drug lonafarnib as a first-ever treatment for Progeria.

This submission is the culmination of twelve years of research data and four clinical trials, all funded by PRF and made possible by the courageous children and their families, as well as PRF’s wonderful community of donors.

You can read more about this exciting news here.

Our hope is that this drug will be approved, enabling these children and young adults to access lonafarnib – which has been shown to give them stronger hearts and longer lives – by prescription, instead of through a clinical trial.

While 2020 has started off as a difficult year for many, we are happy to share a bit of good news with you. All of us at The Progeria Research Foundation have worked tirelessly to make a meaningful impact on the lives of children and young adults with Progeria.

THANK YOU ALL for supporting the research that not only has brought us to this pivotal point, but also allows us to continue working to discover new drugs that will ultimately cure these extraordinary children.